As well as being used to treat neoplastic diseases (Harrison et al., 2012; Verstovsek et al., 2012), this drug is used successfully to treat children with a type I interferonopathy associated with gain-of-function mutations in TMEM173 (encoding stimulator of interferon genes [STING]), responsible for high childhood morbidity and mortality in affected individuals (Frémond et al., 2016). Here, STING1 is linked to neoplasm.